- April 3, 2018
- Posted by: PharmaScroll
- Category:
A recent study, published in Clinical Neuropharmacology, has displayed potential efficacy of dextromethorphan/quinidine (DMQ) in prophylactic treatment of migraine in Multiple Sclerosis patients.
The study was aimed to assess potential efficacy and safety of dextromethorphan/quinidine (DMQ) in prophylactic treatment of migraine in patients with multiple sclerosis (MS) with superimposed pseudobulbar affect (PBA).
In this open-label observational study at the University of Southern California Comprehensive MS Center, Multiple sclerosis patients with superimposed PBA and comorbid migraine were enrolled. The baseline characteristics included, among other data, frequency and severity of acute migraine attacks and use of migraine relievers. The DMQ was used exclusively per its primary indication — PBA symptoms control — 20/10 mg orally, twice a day for the mean of 4.5 months (the shortest exposure registered was 3 months and the longest, 6 months). To determine whether treatment caused an effect on migraine frequency and severity, the baseline and posttreatment values were compared using nonparametric sign test.
Results of the study:
Thirty-three MS subjects with PBA, who also suffered from migraines, were identified. Twenty-nine subjects had improvement in headache frequency, 4 had no change, and none had worsening (P < 0.001 as compared with the baseline). Twenty-eight subjects had improvement in headache severity, 5 had no change, and none had worsening (P < 0.001).
The research concluded that the study results provide evidence that DMQ shows promise as a candidate for larger clinical studies evaluating its efficacy for the prevention of migraine headaches.
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Migraine, visit https://pharmascroll.com/news-category/migraine/
News Source: https://journals.lww.com/clinicalneuropharm/Abstract/2018/03000/Dextromethorphan_Quinidine_in_Migraine.4.aspx
Image Source: https://www.neurologyadvisor.com/headache-migraine-advisor/migraine-multiple-sclerosis-shared-etiologies/article/735258/